When Astellas declined to exercise its option on AVB-101 — a gene therapy for frontotemporal dementia driven by progranulin mutations — it left behind a $2.18 billion potential deal and a biotech with no clear path forward. Then the nonprofits showed up.
The Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration, operating through their joint Treat FTD Fund, invested in AviadoBio in March 2026 to keep the ASPIRE-FTD trial running after Astellas walked. The Phase 1/2 study has now completed three dose-escalation cohorts with 12 patients enrolled across five countries and three continents, according to AviadoBio's March 2026 update. Early data show dose-dependent rises in cerebrospinal fluid progranulin — the biomarker the therapy is designed to restore — with no serious adverse events and no need for immunosuppression, which is a meaningful safety signal for a CNS gene therapy.
This is not a rescue. The Treat FTD Fund is not a pharmaceutical company. But it is real money at the moment the alternative was a trial that stops.
The nonprofit backstop
The Treat FTD Fund was launched in 2016 by ADDF and AFTD specifically to fill the gap that forms when commercial capital won't go early in FTD clinical trials. Each organization contributes $500,000 annually, and the fund was extended through 2035, according to a 2024 joint announcement. The AVB-101 investment is the fund's highest-profile engagement with a program Big Pharma has abandoned.
Astellas' departure wasn't a verdict on the science. The company's broader pattern tells a different story: it also declined an option on Taysha Gene Therapies' TSHA-102 after the option window closed following a 2025 data transfer, and the option expired in October 2025, leaving Taysha to regain full rights to the program. More tellingly, Astellas closed its South San Francisco gene therapy manufacturing facility, expected to be complete by March 2025, according to BioSpace. This looks less like a portfolio decision and more like a strategic retreat from CNS gene therapy as a class.
Astellas still holds equity in AviadoBio from its equity stake from the 2024 option agreement, according to its 2024 announcement. The option expired; the equity didn't. Whether that matters depends on whether AviadoBio finds a commercial partner or another nonprofit willing to bridge the next phase.
What the data actually show
Twelve patients is a small number. The progranulin elevation is encouraging but early. The field will get a fuller picture at the Alzheimer's Association International Conference in July 2026 and the International Society for Frontotemporal Dementias meeting in October 2026, AviadoBio said. Those readouts will determine whether the biomarker signal translates into something clinically meaningful — and whether the next phase of the trial happens at all.
Two other FTD-GRN gene therapy programs are in Phase 1/2 trials: PR006 from Prevail Therapeutics (now part of Eli Lilly) in the PROCLAIM trial, and PBFT02 from Passage Bio in the upliFT-D trial, according to the FTD Disorders Registry. AVB-101 is not in a race it has already lost — but it is in a race.
Frontotemporal dementia with granulin mutations is not Alzheimer's. Patients are typically diagnosed in their mid-40s to mid-60s — prime working years, peak caregiving responsibilities. The disease attacks behavior, impulse control, language, and executive function before it touches memory. Families describe years of misdiagnosis as psychiatric illness before FTD is confirmed. There are no disease-modifying treatments approved. Nothing slows the decline. Nothing stops it.
The funding model question
What makes this story worth telling isn't the science alone. It's the structural gap it exposes.
Rare neurological diseases with a genetic cause and a clearly defined patient population are, in theory, ideal gene therapy targets. Progranulin mutations cause a predictable, aggressive form of FTD. The biology is understood well enough to design a therapy around it. And yet commercial money stepped away at the moment the therapy needed it most — just before pivotal development begins. The nonprofit backstop worked here. But the Treat FTD Fund's annual commitment is roughly $1 million combined. That buys time through a critical period. It does not fund a Phase 3.
The deeper question is whether patient-advocacy philanthropy can bridge the valley of death between Phase 1/2 and Phase 3 — where costs escalate by an order of magnitude and pharma's risk calculus should theoretically re-engage. In this case, it might. If the July and October data readouts are strong, a larger pharma partner could still enter. Astellas holding equity means it has an incentive to facilitate that conversation.
AviadoBio raised $80 million in a Series A in December 2021, according to Global Venturing, from investors including NEA, Monograph Capital, LSP, Advent Life Sciences, the Dementia Discovery Fund, F-Prime Capital, JJDC, and LifeArc. That runway does not fund a pivotal trial without a partner or another financing event. The nonprofit money bought time. It did not buy certainty.
What happens next will tell us something real about whether this model scales — or whether it was always a bridge to somewhere else.
